骨質疏鬆症市場預測

Abstract

Introduction

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Key reasons to purchase this research

• Understand current and future osteoporosis drug market dynamics
• Gain insight into the unmet needs of current osteoporosis treatment and to what extent pipeline drugs will address these issues
• Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK

Table of Contents

OVERVIEW

• This product contains forecasts for osteoporosis drugs across the seven major markets from 2009 to 2018. It has been designed for delivery in an excel data pack format.
  • The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  • Introduction
  • Scope of this research
  • Research and analysis highlights
  • Key reasons to read this report

• Forecasting Methodology
  • The forecasting model:
  • General event information:
  • Event selection and quantification:
  • Event parameters: